New portable and ready-to-use upper respiratory drug delivery solution

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.
Aptar Pharma has released an industry first - PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.
PureHale was officially launched this week at CPHI Worldwide in Madrid and was a finalist in the CPHI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.
With the ongoing rise in pollution the need for upper respiratory relief is more prominent than ever. PureHale’s innovative technology distributes a continuous fine mist that gently cleanses, moisturizes and soothes the upper respiratory tract, in turn helping to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.
PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Developed after researching and analysing the benefits and challenges of traditional nebulizer technology, this new user-friendly system was engineered for on-the-go consumers. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir.
The PureHale technology platform benefits include the following:
Guenter Nadler, Director Business Development at Aptar Pharma, said: “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”
Utilizing Aptar Pharma’s well-established Bag-on-Valve technology, the PureHale system preserves the integrity of the treatment solution while utilizing compressed air/nitrogen between the bag and can to create a continuous mist when actuated. This solution is valuable to pharmaceutical partners seeking a system that can carry a range of formulations, comes in various container sizes, while also offering differentiating and branding advantages.
“PureHale enables pharmaceutical partners to expand their audience reach for their brand formulations, providing portable, symptomatic relief for upper respiratory system conditions,” said Thomas Klofac, President of Aptar Pharma’s Consumer Healthcare Division. PureHale provides brand differentiation via a range of personalization options and, with minimal parameter changes, existing filling processes can be easily adapted to fill PureHale. Aptar Pharma has extensive regulatory experience and this, combined with several standardized solutions, can satisfy a rapid-to-market launch objective.”

Related News
-
News CPHI North America Lookahead: Facilitating ‘meaningful conversations’ on needs and solutions
CPHI NA takes place as a SMART event this year, with online learning and networking from May 9-27 and an in-person event from May 17-19 in Philadelphia, PA. -
News Early development demand continues to boost prospects for smaller CDMOs: CPHI Worldwide panel
The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market -
News CPHI Worldwide is back, and this time it’s hybrid
A new in-person and online edition of CPHI Worldwide, transforming your event experience. -
News 5 Highlights from the Pharmapack Europe Content Programme
Pharmapack Europe is back! Join us online from 27 September as we kick off our two-week long content programme, a great precursor to the in-person event from 13-14 October at the Paris Expo Porte de Versailles. -
News Finding the right experts and collaborating at speed essential to COVID-19 vaccine rollout, says CPHI panel
CPHI Discover webinar examines the progress made so far in terms of vaccine distribution to the global population as well as anticipating future challenges -
News UPDATED: The CPHI Discover Blog
Bookmark this page for regular updates on the rich variety of content coming your way via CPHI Discover, pharma’s largest ever virtual gathering, over the course of our three-day agenda -
News COVID-19 has exacerbated contract manufacturing challenges but industry continues to respond well to crisis: experts
Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told -
News APIs, excipients and formulation: the bedrock of medical innovation
Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in APIs, Ingredients & Formulation
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance